BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205
(BMS-986205) when given together with nivolumab and how well it works as first or second line
therapy in treating patients with liver cancer. BMS-986205 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving
BMS-986205 and nivolumab may work better in treating patients with liver cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Edward Kim
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)